Long‐term impact of delay in assessment of patients with early arthritis
Top Cited Papers
Open Access
- 18 August 2010
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 62 (12) , 3537-3546
Abstract
Objective: During the last decade, rheumatologists have learned to initiate disease‐modifying antirheumatic drugs (DMARDs) early to improve the outcome of rheumatoid arthritis (RA). However, the effect of delay in assessment by a rheumatologist on the outcome of RA has scarcely been explored. The purpose of this study was to examine the association between delay in assessment by a rheumatologist, rates of joint destruction, and probability of achieving DMARD‐free remission in patients with RA. Patient characteristics associated with components of delay (by the patient, by the general practitioner [GP], and overall) were assessed.Methods: A total of 1,674 early arthritis patients from the Leiden Early Arthritis Clinic cohort were evaluated for patient delay, GP delay, and total delay in assessment by a rheumatologist. Among 598 RA patients, associations between total delay, achievement of sustained DMARD‐free remission, and the rate of joint destruction over 6 years followup were determined.Results: The median patient, GP, and total delays in seeing a rheumatologist among patients with early arthritis were 2.4 weeks, 8.0 weeks, and 13.7 weeks, respectively. Among all diagnoses, those diagnosed as having RA or spondylarthritis had the longest total delay (18 weeks). Among the RA patients, 69% were assessed in ≥12 weeks; this was associated with a hazard ratio of 1.87 for not achieving DMARD‐free remission and a 1.3 times higher rate of joint destruction over 6 years, as compared with assessment in <12 weeks. Older age, female sex, gradual symptom onset, involvement of the small joints, lower levels of C‐reactive protein, and the presence of autoantibodies were associated with longer total delay.Conclusion: Only 31% of the RA patients were assessed in <12 weeks of symptom onset. Assessment in <12 weeks is associated with less joint destruction and a higher chance of achieving DMARD‐free remission as compared with a longer delay in assessment. These results imply that attempts to diminish the delay in seeing a rheumatologist will improve disease outcome in patients with RA.Keywords
This publication has 24 references indexed in Scilit:
- Prevalence of and predictive factors for sustained disease‐modifying antirheumatic drug–free remission in rheumatoid arthritis: Results from two large early arthritis cohortsArthritis & Rheumatism, 2009
- Long‐term impact of early treatment on radiographic progression in rheumatoid arthritis: A meta‐analysisArthritis Care & Research, 2006
- The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: A longitudinal analysisArthritis & Rheumatism, 2004
- Relationship between inflammation and joint destruction in early rheumatoid arthritis: a mathematical descriptionAnnals of the Rheumatic Diseases, 2004
- Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritisRheumatology, 2004
- Radiological outcome after four years of early versus delayed treatment strategy in patients with recent onset rheumatoid arthritisAnnals of the Rheumatic Diseases, 2004
- Delay to institution of therapy and induction of remission using single‐drug or combination–disease‐modifying antirheumatic drug therapy in early rheumatoid arthritisArthritis & Rheumatism, 2002
- The therapeutic approach of early intervention for rheumatoid arthritis: what is the evidence?Rheumatology, 2001
- Early effective suppression of inflammation in rheumatoid arthritis reduces radiographic progressionRheumatology, 1998
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988